FDA Shortens Initial IMDELLTRA Monitoring for Patients With ES-SCLC

The U.S. Food and Drug Administration has reduced the recommended monitoring period for the first two doses of Amgen’s IMDELLTRA (tarlatamab-dlle) from 22–24 hours to 6–8 hours in patients with extensive-stage small cell lung cancer (ES-SCLC), a change that could make treatment initiation more practical in community oncology settings.

FDA Reduces Initial Monitoring Requirement

The updated U.S. prescribing information requires patients receiving IMDELLTRA to be monitored for 6–8 hours from the start of each of their first two infusions in an appropriate healthcare setting. The previous recommendation called for 22–24 hours of monitoring.

Patients will also undergo a follow-up assessment, including vital signs, the day after each of these initial doses, on Cycle 1 Days 2 and 9.

The change reduces the time patients must spend in a healthcare facility during the most intensive part of treatment initiation, while retaining post-dose assessment and other safety requirements.

CRS and ICANS Underpin Early Monitoring

The intensive monitoring requirements reflect the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), serious immune-mediated toxicities associated with tarlatamab that carry boxed warnings in the U.S. prescribing information.

The previous 22–24-hour observation period could therefore impose substantial logistical demands on patients and treatment centers. Depending on local practice and available facilities, prolonged monitoring could require an overnight stay, adding travel, scheduling and caregiver burdens for patients with an aggressive cancer.

The revised 6–8-hour window does not eliminate these safety considerations. Instead, it shortens the initial observation period while maintaining next-day assessment and requirements for proximity to appropriate medical care.

Potential Shift Toward Community-Based Treatment

The change could be particularly relevant to community oncology practices, where an estimated 80–85% of U.S. cancer patients receive care.

A shorter initial monitoring period may make same-day outpatient or community-based administration more practical for appropriately equipped centers. For patients with ES-SCLC, reducing prolonged facility time could also limit the burden of travel and extended stays away from home and support networks.

Beyond the first two doses, the monitoring schedule remains unchanged. Patients continue to require 6–8 hours of monitoring after the third dose on Cycle 1 Day 15 and throughout Cycle 2. Monitoring then decreases to 3–4 hours during Cycles 3–4 and to 2 hours from Cycle 5 onward.

Patients are also required to remain within one hour of an appropriate healthcare setting for 48 hours following the start of the Cycle 1 Day 1 and Day 8 infusions and must have a caregiver during this period.

Tarlatamab Targets DLL3 on SCLC Cells

IMDELLTRA is a bispecific T-cell engager that binds DLL3 on tumor cells and CD3 on T cells. By bringing T cells into contact with DLL3-expressing cancer cells, tarlatamab promotes formation of a cytolytic synapse and activates T-cell-mediated tumor-cell killing.

DLL3 is expressed on the surface of approximately 85–96% of SCLC tumors while showing minimal expression on healthy cells, providing a rationale for selective targeting of the protein.

ES-SCLC remains one of the most aggressive forms of lung cancer. Although first-line platinum-based chemotherapy can produce high initial response rates, most patients experience disease progression and require subsequent treatment.

First-Line Development Continues

The monitoring update comes as Amgen expands tarlatamab development beyond its current post-platinum indication. The company recently reported positive topline overall survival results from the Phase 3 DeLLphi-305 study evaluating IMDELLTRA in combination with IMFINZI (durvalumab) in first-line ES-SCLC.

The company is also evaluating reduced post-infusion monitoring in ongoing studies across other indications and treatment settings. Those data could inform whether monitoring requirements can be shortened further.

For now, the FDA update represents an operational change rather than a change to the therapy’s indication or mechanism. By reducing the initial observation burden while retaining defined safety assessments and proximity requirements, the revised label could make IMDELLTRA easier to deliver in outpatient and community oncology settings.

Reference

FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®, AMGEN, 14 SEPTEMBER 2026